Spruce Biosciences (NASDAQ: SPRB)

Spruce Biosciences Return vs. S&P

Spruce Biosciences Company Info

Spruce Biosciences, Inc. operates as a late-stage biopharmaceutical company, which focuses on the development of novel therapies for rare diseases affecting the endocrine system. The firm is initially developing its wholly-owned product candidate, tildacerfont, as the non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Valuation